Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4500 participants.
Also called NCT06396858
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 4,500 participants
- Sponsor
- Brazilian Clinical Research Institute
- Registry
-
NCT06396858
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06396858. Randomized; quadruple masking; primary purpose prevention. Start 2027-01 (anticipated); primary completion 2028-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
- Acronym
- ARCHIMEDES
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Rivaroxaban 2.5 Mg Oral Tablet
- Intervention (Drug)
- Colchicine 0.5 MG
- Intervention (Drug)
- Placebo Rivaroxaban
- Intervention (Drug)
- Placebo Colchicine
- Lead sponsor
- Brazilian Clinical Research Institute
- Collaborator
- Alliança Diagnostic
Record details
- Record id
cardio:ct-nct06396858- Content hash
0bc018769f195ac3842ff306d532f01f6bb786293e10fc157396a7b9ed4a02bb